Subscribe to Biotech Blueprint, FREE weekly newsletter HERE.

This week, Biotech Blueprint breaks down the crosswinds shaping the industry:
– Novo Nordisk doubles down on AI drug discovery with an $812M Deep Apple partnership
– The FDA approves UroGen’s bladder cancer drug Zusduri, the first non-surgical option for NMIBC
– Gilead’s HIV program hits a clinical hold, but shares rebound as lenacapavir’s PDUFA nears
– RFK Jr. removes the entire CDC vaccine panel, replacing members with mRNA skeptics
– Senators Sanders and King reignite the push to ban direct-to-consumer drug ads
– CRISPR Therapeutics rides the FDA’s accelerated approval momentum
– Vaxart surges on promising data for its oral norovirus vaccine

Subscribe to stay ahead of the science, policy, and market signals shaping biotech.